Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G van der Zee

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Clinical and Experimental Immunology|October 17, 2007
Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasiaJ Visser, H W Nijman, B-N Hoogenboom, et al.
Cancer|February 15, 1995
Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet countsA G van der Zee, E M de Cuyper, P C Limburg, et al.
Gynecologic Oncology|August 1, 1995
Cell biological markers of drug resistance in ovarian carcinomaA G van der Zee, H H Hollema, H W de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulvaJ A de Hullu, H Hollema, D A Piers, et al.
British Journal of Cancer|April 17, 1999
Ovarian cysts in women receiving tamoxifen for breast cancerM J Mourits, E G de Vries, P H Willemse, et al.
American Journal of Human Genetics|October 16, 1999
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutationsY Wu, M J Berends, R G Mensink, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancerR S de Jong, P H Willemse, H Boonstra, et al.
Minerva Ginecologica|April 18, 2000
[Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma]D Katsaros, S Fracchioli, H J Arts, et al.
British Journal of Cancer|December 18, 2001
A phase I and pharmacokinetic study of intraperitoneal topotecanL S Hofstra, A M Bos, E G de Vries, et al.
British Journal of Cancer|June 27, 2002
Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapyM J Mourits, I Böckermann, E G de Vries, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Immunology|October 17, 2007
Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasiaJ Visser, H W Nijman, B-N Hoogenboom, et al.
Cancer|February 15, 1995
Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet countsA G van der Zee, E M de Cuyper, P C Limburg, et al.
Gynecologic Oncology|August 1, 1995
Cell biological markers of drug resistance in ovarian carcinomaA G van der Zee, H H Hollema, H W de Bruijn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2000
Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulvaJ A de Hullu, H Hollema, D A Piers, et al.
British Journal of Cancer|April 17, 1999
Ovarian cysts in women receiving tamoxifen for breast cancerM J Mourits, E G de Vries, P H Willemse, et al.
American Journal of Human Genetics|October 16, 1999
Association of hereditary nonpolyposis colorectal cancer-related tumors displaying low microsatellite instability with MSH6 germline mutationsY Wu, M J Berends, R G Mensink, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancerR S de Jong, P H Willemse, H Boonstra, et al.
Minerva Ginecologica|April 18, 2000
[Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma]D Katsaros, S Fracchioli, H J Arts, et al.
British Journal of Cancer|December 18, 2001
A phase I and pharmacokinetic study of intraperitoneal topotecanL S Hofstra, A M Bos, E G de Vries, et al.
British Journal of Cancer|June 27, 2002
Tamoxifen effects on subjective and psychosexual well-being, in a randomised breast cancer study comparing high-dose and standard-dose chemotherapyM J Mourits, I Böckermann, E G de Vries, et al.
Pageof 8